Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Royalty Pharma
Pharma
For 2nd time in three months, Syndax wins FDA nod for a new drug
Syndax has gained an FDA new drug approval for the 2nd time in three months, scoring with Revuforj to treat patients with a genetic form of leukemia.
Kevin Dunleavy
Nov 18, 2024 11:09am
Syndax strikes $350M funding deal with Royalty Pharma
Nov 5, 2024 10:50am
In a first, FDA approves Servier's Voranigo in low-grade gliomas
Aug 6, 2024 5:25pm
Teva taps Royalty to bankroll long-acting schizophrenia drug
Nov 13, 2023 11:40am
Royalty commits up to $1.5B for most of PTC's Evrysdi royalties
Oct 19, 2023 11:13am
Royalty Pharma strikes $150M Skytrofa royalty deal with Ascendis
Sep 6, 2023 11:28am